Effect of Hydroxychloroquine on Clinical Status

JAMA

EMBARGOED FOR RELEASE: 11 A.M. (ET), MONDAY, NOVEMBER 9, 2020

Media advisory: The full study and editorial are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2020.22240?guestAccessKey=b640b657-02f3-4eb9-9bd5-beed8b9d4410&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=110920

 

What The Study Did: This randomized trial compares the effects of hydroxychloroquine versus placebo on patients’ clinical status at 14 days (home, requiring noninvasive or invasive ventilation or extracorporeal membrane oxygenation, hospitalized, died) among adults hospitalized with COVID-19.

Authors: Wesley H. Self, M.D., M.P.H., of the Vanderbilt University Medical Center in Nashville, Tennessee, is the corresponding author.

(doi:10.1001/jama.2020.22240)

 

Editor’s Note: The article includes conflict of interest and funding/support disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.